- Aging Out of Medicaid Coverage and Survival After Pediatric Liver Transplanton October 29, 2025
This cohort study assesses the association between Medicaid coverage disruptions and short- and long-term survival outcomes among recipients of pediatric liver transplants.
- Vaccine-Preventable Infectious Diseases Within US Immigration Detention Centerson October 22, 2025
This case series examines epidemiological patterns of 3 vaccine-preventable diseases within US Immigration and Customs Enforcement facilities.
- Viral Infections Related to Injection Drug Useon October 21, 2025
This JAMA Insights discusses common viral infections associated with injection drug use, including HIV and hepatitis, as well as strategies for prevention.
- Patient Information: Viral Infections Related to Injection Drug Useon October 21, 2025
This JAMA Patient Page describes viral infections that are associated with injection drug use, screening and vaccination practices, and behaviors that reduce risk of infection.
- Isolated Hepatitis B Virus—A Rare Cause of Brain Damageon October 1, 2025
This case report describes a 23-year-old pregnant woman presenting with seizures and chronic hepatitis B, with hyperintense lesions discovered in the left caudate nucleus on magnetic resonance imaging.
- Isolated Hepatitis B Virus—A Rare Cause of Brain Damageon October 1, 2025
This case report describes a 23-year-old pregnant woman presenting with seizures and chronic hepatitis B, with hyperintense lesions discovered in the left caudate nucleus on magnetic resonance imaging.
- HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccineon September 9, 2025
This study provides the end-of-study results on the durability of seroprotection response in a trial comparing 2- and 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG) vs 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant.
- HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccineon September 9, 2025
This study provides the end-of-study results on the durability of seroprotection response in a trial comparing 2- and 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG) vs 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant.
